Portal de Periódicos da CAPES

PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival

2015; Impact Journals LLC; Volume: 6; Issue: 32 Linguagem: Inglês

10.18632/oncotarget.5028

1949-2553

Wenfeng Fang, Shaodong Hong, Nan Chen, Xiaobo He, Jianhua Zhan, Tao Qin, Ting Zhou, Zhihuang Hu, Yuxiang Ma, Yuanyuan Zhao, Ying Tian, Yunpeng Yang, Cong Xue, Yanna Tang, Yan Huang, Hongyun Zhao, Li Zhang,

Cancer Immunotherapy and Biomarkers

// Wenfeng Fang 1, 2, * , Shaodong Hong 1, 2, * , Nan Chen 3, * , Xiaobo He 3 , Jianhua Zhan 1, 2 , Tao Qin 1, 2 , Ting Zhou 1, 2 , Zhihuang Hu 1, 2 , Yuxiang Ma 1, 2 , Yuanyuan Zhao 1, 2 , Ying Tian 1, 2 , Yunpeng Yang 1, 2 , Cong Xue 1, 2 , Yanna Tang 3 , Yan Huang 1, 2 , Hongyun Zhao 1, 2 , Li Zhang 1, 2 1 State Key laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China 2 Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China 3 Department of Oncology, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China * These authors have contributed equally to this work Correspondence to: Li Zhang, e-mail: zhangli@sysucc.org.cn Keywords: pulmonary lymphoepithelioma-like carcinoma, PD-L1, Epstein–Barr virus Received: May 07, 2015 Accepted: August 14, 2015 Published: August 24, 2015 ABSTRACT Backgroud: Programmed cell death-ligand 1 (PD-L1) and driver mutations are commonly seen in non-small-cell lung cancer (NSCLC). However, the prevelance of PD-L1 over-expression and its prognostic value in Epstein–Barr virus (EBV) associated pulmonary lymphoepithelioma-like carcinoma (LELC) remains poorly understood. Methods: A total of 214 NSCLC patients and 113 surgically treated pulmonary LELC patients were included. Paraffin-embedded tumor sections were stained with PD-L1 antibody. Correlations between PD-L1 expression and clinicopathological features as well as survival outcomes were analyzed. Results: The frequency of PD-L1 over-expression in NSCLC was 51.4%. No significant association was observed between common driver mutations and PD-L1 over-expression. Remakably, the positive rate of PD-L1 in pulmonary LELC was 74.3%. High PD-L1 expression was associated with impaired diseas-free survival (DFS) compared with low PD-L1 expression ( p = 0.008). Multivariate analysis shows that PD-L1 expression level, N stage and M stage were independent prognostic factors for DFS. N stage and M stage but not PD-L1 expression level were significantly associated with overall survival (OS). Conclusions: PD-L1 over-expression was not related to common driver mutations in NSCLC. Pulmonary LELC have remarkably high incidence of PD-L1 expression. PD-L1 was a negative prognostic factor for DFS in surgically resected pulmonary LELC. These findings may provide a rationale for immunotarget therapy in this virus-associated lung cancer.